A citation-based method for searching scientific literature

Martin J Landray, Richard Haynes, Jemma C Hopewell, Sarah Parish, Theingi Aung, Joseph Tomson, Karl Wallendszus, Martin Craig, Lixin Jiang, Rory Collins, Jane Armitage. N Engl J Med 2014
Times Cited: 947







List of co-cited articles
1272 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.
William E Boden, Jeffrey L Probstfield, Todd Anderson, Bernard R Chaitman, Patrice Desvignes-Nickens, Kent Koprowicz, Ruth McBride, Koon Teo, William Weintraub. N Engl J Med 2011
67

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Deepak L Bhatt, P Gabriel Steg, Michael Miller, Eliot A Brinton, Terry A Jacobson, Steven B Ketchum, Ralph T Doyle, Rebecca A Juliano, Lixia Jiao, Craig Granowitz,[...]. N Engl J Med 2019
37

Effects of dalcetrapib in patients with a recent acute coronary syndrome.
Gregory G Schwartz, Anders G Olsson, Markus Abt, Christie M Ballantyne, Philip J Barter, Jochen Brumm, Bernard R Chaitman, Ingar M Holme, David Kallend, Lawrence A Leiter,[...]. N Engl J Med 2012
32

Effects of torcetrapib in patients at high risk for coronary events.
Philip J Barter, Mark Caulfield, Mats Eriksson, Scott M Grundy, John J P Kastelein, Michel Komajda, Jose Lopez-Sendon, Lori Mosca, Jean-Claude Tardif, David D Waters,[...]. N Engl J Med 2007
30

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease.
Louise Bowman, Jemma C Hopewell, Fang Chen, Karl Wallendszus, William Stevens, Rory Collins, Stephen D Wiviott, Christopher P Cannon, Eugene Braunwald, Emily Sammons,[...]. N Engl J Med 2017
480
28

Effects of combination lipid therapy in type 2 diabetes mellitus.
Henry N Ginsberg, Marshall B Elam, Laura C Lovato, John R Crouse, Lawrence A Leiter, Peter Linz, William T Friedewald, John B Buse, Hertzel C Gerstein, Jeffrey Probstfield,[...]. N Engl J Med 2010
27

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
Marc S Sabatine, Robert P Giugliano, Anthony C Keech, Narimon Honarpour, Stephen D Wiviott, Sabina A Murphy, Julia F Kuder, Huei Wang, Thomas Liu, Scott M Wasserman,[...]. N Engl J Med 2017
24

Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study.
Benjamin F Voight, Gina M Peloso, Marju Orho-Melander, Ruth Frikke-Schmidt, Maja Barbalic, Majken K Jensen, George Hindy, Hilma Hólm, Eric L Ding, Toby Johnson,[...]. Lancet 2012
24

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.
François Mach, Colin Baigent, Alberico L Catapano, Konstantinos C Koskinas, Manuela Casula, Lina Badimon, M John Chapman, Guy G De Backer, Victoria Delgado, Brian A Ference,[...]. Eur Heart J 2020
24

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
Christopher P Cannon, Michael A Blazing, Robert P Giugliano, Amy McCagg, Jennifer A White, Pierre Theroux, Harald Darius, Basil S Lewis, Ton Oude Ophuis, J Wouter Jukema,[...]. N Engl J Med 2015
23

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
Gregory G Schwartz, P Gabriel Steg, Michael Szarek, Deepak L Bhatt, Vera A Bittner, Rafael Diaz, Jay M Edelberg, Shaun G Goodman, Corinne Hanotin, Robert A Harrington,[...]. N Engl J Med 2018
22

Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease.
A Michael Lincoff, Stephen J Nicholls, Jeffrey S Riesmeyer, Philip J Barter, H Bryan Brewer, Keith A A Fox, C Michael Gibson, Christopher Granger, Venu Menon, Gilles Montalescot,[...]. N Engl J Med 2017
360
21


Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
A Keech, R J Simes, P Barter, J Best, R Scott, M R Taskinen, P Forder, A Pillai, T Davis, P Glasziou,[...]. Lancet 2005
19

Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk.
Michelle L O'Donoghue, Sergio Fazio, Robert P Giugliano, Erik S G Stroes, Estella Kanevsky, Ioanna Gouni-Berthold, KyungAh Im, Armando Lira Pineda, Scott M Wasserman, Richard Češka,[...]. Circulation 2019
233
18

Major lipids, apolipoproteins, and risk of vascular disease.
Emanuele Di Angelantonio, Nadeem Sarwar, Philip Perry, Stephen Kaptoge, Kausik K Ray, Alexander Thompson, Angela M Wood, Sarah Lewington, Naveed Sattar, Chris J Packard,[...]. JAMA 2009
18

Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis.
Mitsuhiro Yokoyama, Hideki Origasa, Masunori Matsuzaki, Yuji Matsuzawa, Yasushi Saito, Yuichi Ishikawa, Shinichi Oikawa, Jun Sasaki, Hitoshi Hishida, Hiroshige Itakura,[...]. Lancet 2007
17

Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer.
JoAnn E Manson, Nancy R Cook, I-Min Lee, William Christen, Shari S Bassuk, Samia Mora, Heike Gibson, Christine M Albert, David Gordon, Trisha Copeland,[...]. N Engl J Med 2019
358
16

Lipoprotein(a) Reduction in Persons with Cardiovascular Disease.
Sotirios Tsimikas, Ewa Karwatowska-Prokopczuk, Ioanna Gouni-Berthold, Jean-Claude Tardif, Seth J Baum, Elizabeth Steinhagen-Thiessen, Michael D Shapiro, Erik S Stroes, Patrick M Moriarty, Børge G Nordestgaard,[...]. N Engl J Med 2020
196
16

Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial.
Stephen J Nicholls, A Michael Lincoff, Michelle Garcia, Dianna Bash, Christie M Ballantyne, Philip J Barter, Michael H Davidson, John J P Kastelein, Wolfgang Koenig, Darren K McGuire,[...]. JAMA 2020
135
16

Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus.
Louise Bowman, Marion Mafham, Karl Wallendszus, Will Stevens, Georgina Buck, Jill Barton, Kevin Murphy, Theingi Aung, Richard Haynes, Jolyon Cox,[...]. N Engl J Med 2018
277
15


Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome.
Vera A Bittner, Michael Szarek, Philip E Aylward, Deepak L Bhatt, Rafael Diaz, Jay M Edelberg, Zlatko Fras, Shaun G Goodman, Sigrun Halvorsen, Corinne Hanotin,[...]. J Am Coll Cardiol 2020
113
15

High-Density Lipoprotein Cholesterol and Cause-Specific Mortality in Individuals Without Previous Cardiovascular Conditions: The CANHEART Study.
Dennis T Ko, David A Alter, Helen Guo, Maria Koh, Geoffrey Lau, Peter C Austin, Gillian L Booth, William Hogg, Cynthia A Jackevicius, Douglas S Lee,[...]. J Am Coll Cardiol 2016
143
14

Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study.
Aruna D Pradhan, Nina P Paynter, Brendan M Everett, Robert J Glynn, Pierre Amarenco, Marshall Elam, Henry Ginsberg, William R Hiatt, Shun Ishibashi, Wolfgang Koenig,[...]. Am Heart J 2018
149
14

Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease.
Brian A Ference, John J P Kastelein, Kausik K Ray, Henry N Ginsberg, M John Chapman, Chris J Packard, Ulrich Laufs, Clare Oliver-Williams, Angela M Wood, Adam S Butterworth,[...]. JAMA 2019
229
13

Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality.
Sebhat Erqou, Stephen Kaptoge, Philip L Perry, Emanuele Di Angelantonio, Alexander Thompson, Ian R White, Santica M Marcovina, Rory Collins, Simon G Thompson, John Danesh. JAMA 2009
916
13


Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
C Baigent, L Blackwell, J Emberson, L E Holland, C Reith, N Bhala, R Peto, E H Barnes, A Keech, J Simes,[...]. Lancet 2010
12

Lipoprotein(a) as a cardiovascular risk factor: current status.
Børge G Nordestgaard, M John Chapman, Kausik Ray, Jan Borén, Felicita Andreotti, Gerald F Watts, Henry Ginsberg, Pierre Amarenco, Alberico Catapano, Olivier S Descamps,[...]. Eur Heart J 2010
985
12

Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.
Nicholas J Viney, Julian C van Capelleveen, Richard S Geary, Shuting Xia, Joseph A Tami, Rosie Z Yu, Santica M Marcovina, Steven G Hughes, Mark J Graham, Rosanne M Crooke,[...]. Lancet 2016
383
12

High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
D J Gordon, J L Probstfield, R J Garrison, J D Neaton, W P Castelli, J D Knoke, D R Jacobs, S Bangdiwala, H A Tyroler. Circulation 1989
12

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Scott M Grundy, Neil J Stone, Alison L Bailey, Craig Beam, Kim K Birtcher, Roger S Blumenthal, Lynne T Braun, Sarah de Ferranti, Joseph Faiella-Tommasino, Daniel E Forman,[...]. Circulation 2019
771
12

Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks: Meta-analysis of 10 Trials Involving 77 917 Individuals.
Theingi Aung, Jim Halsey, Daan Kromhout, Hertzel C Gerstein, Roberto Marchioli, Luigi Tavazzi, Johanna M Geleijnse, Bernhard Rauch, Andrew Ness, Pilar Galan,[...]. JAMA Cardiol 2018
335
11

HDL cholesterol efflux capacity and incident cardiovascular events.
Anand Rohatgi, Amit Khera, Jarett D Berry, Edward G Givens, Colby R Ayers, Kyle E Wedin, Ian J Neeland, Ivan S Yuhanna, Daniel R Rader, James A de Lemos,[...]. N Engl J Med 2014
834
11

Remnant cholesterol as a causal risk factor for ischemic heart disease.
Anette Varbo, Marianne Benn, Anne Tybjærg-Hansen, Anders B Jørgensen, Ruth Frikke-Schmidt, Børge G Nordestgaard. J Am Coll Cardiol 2013
505
11

Genetic variants associated with Lp(a) lipoprotein level and coronary disease.
Robert Clarke, John F Peden, Jemma C Hopewell, Theodosios Kyriakou, Anuj Goel, Simon C Heath, Sarah Parish, Simona Barlera, Maria Grazia Franzosi, Stephan Rust,[...]. N Engl J Med 2009
822
11

Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis.
Stephen Burgess, Brian A Ference, James R Staley, Daniel F Freitag, Amy M Mason, Sune F Nielsen, Peter Willeit, Robin Young, Praveen Surendran, Savita Karthikeyan,[...]. JAMA Cardiol 2018
197
11

Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association.
Don P Wilson, Terry A Jacobson, Peter H Jones, Marlys L Koschinsky, Catherine J McNeal, Børge G Nordestgaard, Carl E Orringer. J Clin Lipidol 2019
121
11

Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial.
Matthew J Budoff, Deepak L Bhatt, April Kinninger, Suvasini Lakshmanan, Joseph B Muhlestein, Viet T Le, Heidi T May, Kashif Shaikh, Chandana Shekar, Sion K Roy,[...]. Eur Heart J 2020
88
12

Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis.
Amit V Khera, Marina Cuchel, Margarita de la Llera-Moya, Amrith Rodrigues, Megan F Burke, Kashif Jafri, Benjamin C French, Julie A Phillips, Megan L Mucksavage, Robert L Wilensky,[...]. N Engl J Med 2011
11

Effect of Serial Infusions of CER-001, a Pre-β High-Density Lipoprotein Mimetic, on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial: A Randomized Clinical Trial.
Stephen J Nicholls, Jordan Andrews, John J P Kastelein, Bela Merkely, Steven E Nissen, Kausik K Ray, Gregory G Schwartz, Stephen G Worthley, Connie Keyserling, Jean-Louis Dasseux,[...]. JAMA Cardiol 2018
76
14

Triglycerides and cardiovascular disease.
Børge G Nordestgaard, Anette Varbo. Lancet 2014
604
10

Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT.
Deepak L Bhatt, Ph Gabriel Steg, Michael Miller, Eliot A Brinton, Terry A Jacobson, Steven B Ketchum, Ralph T Doyle, Rebecca A Juliano, Lixia Jiao, Craig Granowitz,[...]. J Am Coll Cardiol 2019
127
10

Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial.
Stephen J Nicholls, A Michael Lincoff, Dianna Bash, Christie M Ballantyne, Philip J Barter, Michael H Davidson, John J P Kastelein, Wolfgang Koenig, Darren K McGuire, Dariush Mozaffarian,[...]. Clin Cardiol 2018
124
10

Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid.
R Preston Mason, Peter Libby, Deepak L Bhatt. Arterioscler Thromb Vasc Biol 2020
84
11

Effect of Infusion of High-Density Lipoprotein Mimetic Containing Recombinant Apolipoprotein A-I Milano on Coronary Disease in Patients With an Acute Coronary Syndrome in the MILANO-PILOT Trial: A Randomized Clinical Trial.
Stephen J Nicholls, Rishi Puri, Christie M Ballantyne, J Wouter Jukema, John J P Kastelein, Wolfgang Koenig, R Scott Wright, David Kallend, Peter Wijngaard, Marilyn Borgman,[...]. JAMA Cardiol 2018
73
13

Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction.
Anders Berg Jørgensen, Ruth Frikke-Schmidt, Anders Sode West, Peer Grande, Børge G Nordestgaard, Anne Tybjærg-Hansen. Eur Heart J 2013
231
9

Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis.
P M Kearney, L Blackwell, R Collins, A Keech, J Simes, R Peto, J Armitage, C Baigent. Lancet 2008
9

Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease.
Ruth Frikke-Schmidt, Børge G Nordestgaard, Maria C A Stene, Amar A Sethi, Alan T Remaley, Peter Schnohr, Peer Grande, Anne Tybjaerg-Hansen. JAMA 2008
341
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.